Indication intelligence, analysis and sector perception

Capricor (CAPR) bites the bullet that they fired at itself

May 12, 2017 5:42pm

Shares of CAPR closed down - $1.89 or -62% to $1.16 and is now laying-off employees following the failure of its mid-stage cardiovascular drug trial while the controversial CEO remains at the helm ...

Shares of Capricor fell -$1.89 per share to close at $1.16 having closed Thursday at $3.05 in wake of the reported failure of its P2 Allstar trial.

The 142-patient trial was assessing the efficacy of CAP-1002 (allogeneic cardiosphere-derived cells) in adults who have experienced a large heart attack with residual cardiac dysfunction. In its Thursday announcement, Capricor said the mid stage trial demonstrated a low probability of achieving a statistically-significant difference in the 12-month primary efficacy endpoint of percent change from baseline infarct size.

Bottom Line: Capricor performed a six-month data test and discovered there was NO notable difference between the patients who received the treatment and those who received a placebo especially with respect to the change in ejection fraction. They can KISS the Jansen (J&J) deal good-bye! CAPR will focus on CAP-1002 in in boys and young men with Duchenne muscular dystrophy (DMD).

A change in management is needed. CAPR should kiss the new investors in the latest <last week> $3.7 M private placement priced at $3.10 which closed on 5/10/17 as CAPR’s share pricing tanked.

I see a $1.00 in the close future …

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.